Inventor
Steven C. Quay
Inventor
Edmonds, WA, US
Overview
Patents· 85 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes33%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations14%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests8%
Y10TTechnical subjects covered by former us classification7%
C07DHeterocyclic compounds7%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium7%
G01RMeasuring electric variables6%
C07CAcyclic or carbocyclic compounds3%
C12NMicroorganisms or enzymes3%
G01NInvestigating or analysing materials by determining their chemical or physical properties3%
PatentTitleYear
9,731,016'Tyrosine-based lipids for delivery of therapeutics'20179,415,007'Cyanocobalamin low viscosity aqueous formulations for intranasal delivery'20169,339,461'Arginine-based lipids for delivery of therapeutics'20169,295,658'Second generation fatty acid compositions, formulations, and methods of use and synthesis thereof'20169,074,205'Nicked or gapped nucleic acid molecules and uses thereof'20159,052,318'Absorbent paper and use thereof for breast cancer detection'20159,023,793'Intranasal carbetocin formulations and methods for the treatment of autism'20158,940,714'Cyanocobalamin low viscosity aqueous formulations for intranasal delivery'20158,877,729'Amino acid lipids and uses thereof'20148,501,824'Amino acid lipids and uses thereof'20138,486,891'Nasal calcitonin formulations containing chlorobutanol'20138,138,149'Nasal calcitonin formulations containing chlorobutanol'20128,063,178'Phage displayed Trp cage ligands'20118,003,353'Cyanocobalamin low viscosity aqueous formulations for intranasal delivery'20117,939,505'Amino acid lipids and uses thereof'20117,879,349'Cyanocobalamin low viscosity aqueous formulations for intranasal delivery'20117,863,245'Compositions for enhanced epithelial permeation of neuropeptide Y for treating obesity'20117,812,120'Nasal calcitonin formulations containing chlorobutanol'20107,560,572'Production and use of derivatized homoserine lactones'20097,435,720'Compositions and methods for enhanced mucosal delivery of parathyroid hormone'20087,404,489'Cyanocobalamin low viscosity aqueous formulations for intranasal delivery'20087,329,725'Phage displayed Trp cage ligands'20087,244,709'Compositions and methods for enhanced mucosal delivery of parathyroid hormone'20077,229,966'Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity'20077,229,636'Cyanocobalamin low viscosity aqueous formulations for intranasal delivery'20077,186,691'Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity'20077,186,692'Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity'20077,166,575'Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity'20077,157,426'Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity'20077,128,877'Methods and devices for obtaining and assaying mammary fluid samples for evaluating breast diseases, including cancer'20067,030,155'Emulsion vehicle for poorly soluble drugs'20066,982,282'Emulsion vehicle for poorly soluble drugs'20066,894,026'Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders'20056,887,210'Devices and methods for obtaining mammary fluid samples for evaluating breast diseases, including cancer'20056,875,420'Method of ultrasound imaging'20056,727,280'Method for treating colorectal carcinoma using a taxane/tocopherol formulation'20046,723,303'Ultrasound contrast agents including protein stabilized microspheres of perfluoropropane, perfluorobutane or perfluoropentane'20046,703,513'Production and use of derivatized homoserine lactones'20046,689,073'Methods and devices for collecting, handling and processing mammary fluid samples for evaluating breast diseases, including cancer'20046,667,048'Emulsion vehicle for poorly soluble drugs'20036,660,286'Emulsion vehicle for poorly soluble drugs'20036,620,404'Gaseous ultrasound contrast media and method for selecting gases for use as ultrasound contrast media'20036,569,404'Phase shift colloids as ultrasound contrast agents'20036,458,373'Emulsion vehicle for poorly soluble drugs'20026,444,791'Methods and compositions for the treatment of keratoconus using protease inhibitors'20026,287,521'Methods and devices for obtaining and assaying mammary fluid samples for evaluating breast diseases, including cancer'20016,274,713'Polychelants'20016,245,319'Colloidal dispersions of perfluoropentane'20016,156,292'Gaseous ultrasound contrast media and method for selecting gases for use as ultrasound contrast media'20005,897,851'Nucleation and activation of a liquid-in-liquid emulsion for use in ultrasound imaging'19995,876,696'Composition comprising a fluorine containing surfactant and perfluoropentane for ultrasound'19995,798,266'Methods and kits for obtaining and assaying mammary fluid samples for breast diseases, including cancer'19985,707,607'Phase shift colloids as ultrasound contrast agents'19985,707,606'Phase shift colloids as ultrasound contrast agents'19985,595,723'Method for preparing storage stable colloids'19975,573,751'Persistent gaseous bubbles as ultrasound contrast media'19965,558,853'Phase shift colloids as ultrasound contrast agents'19965,558,854'Ultrasound contrast media comprising perfluoropentane and perfluorohexane gas'19965,558,855'Phase shift colloids as ultrasound contrast agents'19965,409,688'Gaseous ultrasound contrast media'19955,393,524'Methods for selecting and using gases as ultrasound contrast media'19955,364,613'Polychelants containing macrocyclic chelant moieties'19945,223,243'Dipyridoxyl phosphate chelating compound intermediates useful as NMRI contrast agents'19935,219,553'Composition of a n-carboxymethylated tetraazacyclododecane chelating agent, a paramagnetic metal and excess calcium ions for MRI'19935,130,437'N,N\'-bis-(pyridoxal)ethylenediamine-N,N\'-diacetic acid derivatives'19925,130,431'Dipyriodoxyl phosphate chelating compound intermediates'19925,091,169'Dipyridoxyl phosphate NMRI contrast agent compositions'19925,089,644'Preparation of oxamine complexes'19925,087,439'Paramagnetic metal-diethylenetriamine-pentaacetic acid partial amide complexes for magnetic resonance imaging'19925,039,512'NMR imaging with paramagnetic polyvalent metal salts of poly-(acid-alkylene-amino)-alkanes'19915,039,511'Amyloidosis and alzheimer\'s disease diagnostic assay and reagents therefor'19915,008,099'Amyloidosis and Alzheimer\'s disease diagnostic assay and reagents therefor'19914,994,259'Improvement in the method of NMR imaging employing a manganese II chelates of N,N\'-bis[pyridoxal-alkylene (or cycloalkylene) (or arylene)]-N,N\'-diacetic acid derivatives'19914,992,554'Dipyridoxyl phosphate chelating compounds'19914,992,555'Certain dipyridylphosphate chelatable compounds capable of forming metal ion chelates'19914,935,518'Manganese(II), chelate contrast agents derived from N,N\'-bis-(pyridoxal ethylene diamine-N,N\')-diacetic acid and derivatives thereof'19904,933,456'Dipyridoxyl phosphate NMRI contrast agents'19904,933,156'Amyloidosis and Alzheimer\'s disease diagnostic assay and reagents therefor'19904,863,716'Determination of fallopian tubal patency by magnetic resonance imaging'19894,859,451'Paramagnetic contrast agents for MR imaging'19894,842,845'Radioactive metal chelates for dipyridoxyl phosphate'19894,758,422'Ferrioxamine paramagnetic contrast agents for MR imaging'19884,687,658'Metal chelates of diethylenetriaminepentaacetic acid partial esters for NMR imaging'19874,687,659'Diamide-DTPA-paramagnetic contrast agents for MR imaging'19874,637,929'Ferrioxamine-paramagnetic contrast agents for MR imaging, composition, apparatus and use'1987Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1987–2001Patents assigned to SALUTAR INC (24)· patent assignee history
1987–1989Based in Menlo Park, CA, US· patent location history
1989–1993Based in Los Altos Hills, CA, US· patent location history
1994–2015Patents assigned to QUAY STEVEN C (8)· patent assignee history
1995–2006Patents assigned to SONUS PHARMA INC (19)· patent assignee history
1995–2004Based in Pacific Palisades, CA, US· patent location history
1998–2016Based in Edmonds, WA, US· patent location history
2007–2011Patents assigned to NASTECH PHARM CO (9)· patent assignee history
2011–2017Patents assigned to MARINA BIOTECH INC (7)· patent assignee history
2011–2017Based in Seattle, WA, US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| SALUTAR INC | 24 | 1987–2001 |
| SONUS PHARMA INC | 19 | 1995–2006 |
| NASTECH PHARM CO | 9 | 2007–2011 |
| QUAY STEVEN Cself | 8 | 1994–2015 |
| MARINA BIOTECH INC | 7 | 2011–2017 |
Locations
| Location | Patents | Span |
|---|---|---|
| Edmonds, Washington, US | 34 | 1998–2016 |
| Los Altos Hills, California, US | 17 | 1989–1993 |
| Pacific Palisades, California, US | 13 | 1995–2004 |
| Seattle, Washington, US | 8 | 2011–2017 |
| Menlo Park, California, US | 5 | 1987–1989 |